Streetbeat News

IDRSF

Idorsia Ltd

https://www.idorsia.com

CEO

Jean-Paul Clozel

Industry

Pharmaceutical Preparation Manufacturing

Open

2.25

Mkt cap

293M

Volume

1.5K

High

2.25

P/E Ratio

-0.70

52-wk high

2.88

Low

1.31

Div yield

N/A

52-wk low

0.70

Idorsia Ltd announced positive results from a study on daridorexant, showing its effectiveness in treating chronic insomnia and nocturia in patients aged 55 and older. The study highlights improvements in symptoms and daytime functioning, with a good safety profile.

Portfolio Pulse from

March 14, 2025 | 6:15 am

Idorsia Ltd (OTC:IDRSF) held its Q4 2024 earnings call on March 4, 2025, discussing the company's financial results and future outlook. Key participants included executives and analysts from Deutsche Bank and Octavian.

Portfolio Pulse from

March 04, 2025 | 4:15 pm

Idorsia will release its Full Year 2024 Financial Report on March 4, 2025, followed by a webcast and conference call to discuss the results.

Portfolio Pulse from

February 27, 2025 | 5:00 pm

Idorsia and Viatris have updated their collaboration terms for the development and commercialization of selatogrel and cenerimod. Idorsia's development cost contribution is reduced by $100 million, while Viatris' potential payments to Idorsia are reduced by $250 million.

Portfolio Pulse from

February 26, 2025 | 6:15 am

Idorsia Ltd announced the end of an exclusivity agreement for the global rights to aprocitentan, as the undisclosed party did not finalize the deal. Idorsia is now seeking alternative partners.

Portfolio Pulse from

February 26, 2025 | 6:00 am

Idorsia Ltd has announced the agenda for its bondholder meeting on February 25, 2025, concerning its CHF 200 million convertible bond. The unaudited financial status as of December 31, 2024, is available, with audited statements to follow on February 27, 2025.

Portfolio Pulse from

February 12, 2025 | 10:15 pm

Idorsia Ltd is set to present at the J.P. Morgan Healthcare Conference 2025, aiming to create value for stakeholders. The presentation will be available for replay.

Portfolio Pulse from

January 15, 2025 | 11:00 pm

Idorsia Ltd plans to invite bondholders to a meeting regarding its CHF 200 million convertible bond maturing on January 17, 2025. The bond has a conversion price of CHF 6.00 per Idorsia share.

Portfolio Pulse from

January 13, 2025 | 6:15 am

Idorsia Ltd announced a delay in signing a binding agreement for the global rights to aprocitentan. The company is also in discussions with bondholders to restructure its debt and extend its operational cash runway.

Portfolio Pulse from

December 20, 2024 | 6:15 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.